Abstract: Objective To evaluate the clinical efficacy and safety of Anluohuaxian capsule on treating patients with chronic hepatitis B and liver fibrosis. Methods A total of 72 patients with chronic hepatitis B and liver fibrosis were enrolled into this randomized and open clinical study. They were randomly divided into two groups: 37 cases in experimental group and 35 cases in control group. The experimental group were given Anluohuaxian capsule 6.0 g twice a day for six months and the control group were given conventional treatment. Liver and kidney function, blood routine, serum index of liver fibrosis and ultrasound were measured before and after treatment. Results Serum liver fibrosis indexes in experimental group were better than those of control group（P ＜ 0.05）. Portal vein diameter and thickness of the spleen in experimental group were significantly reduced after treatment（P ＜ 0.05）.Conclusions Anluohuaxian capsule is effective and well-tolerated for patients with chronic hepatitis B and liver fibrosis.